Tissue Regeneration Therapeutics gets listed on THE OCMX™

The OCMX™ is pleased to announce the listing of Tissue Regeneration Therapeutics to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

TORONTO, ON, March 24, 2021 /24-7PressRelease/ -- Tissue Regeneration Therapeutics (TRT) is a Canadian life science company based on proprietary, and patented, human umbilical cord tissue technologies that provide a comprehensive product portfolio from skin care products to cell based, and cell engineered, therapeutics.

The OCMX™ is pleased to announce the listing of Tissue Regeneration Therapeutics to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

The OCMX™ has spent considerable time completing its due diligence on Tissue Regeneration Therapeutics and concluded that there is indeed a tremendous potential for this opportunity.

The OCMX™ noted that Tissue Regeneration Therapeutics exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.

WHAT THEY DO

TRT technologies are based on the extraction of cells (MSCs) from the tissue of the human umbilical cord. These cells, which unlike blood cells can be used without the need for matching, possess potent anti-inflammatory, immune-modulatory, and regenerative properties and represent a new class of biological therapeutic. TRT also produces a derivative from such cells to provide an acellular therapeutic and is currently launching this in a cosmetics product.

TRT has licensed its technology to family banking companies who have cryogenically stored TRT cells for thousands of parents in North America and Australia. Through internationally recognized clinician-scientist collaborators we have shown the therapeutic potential of our cells in, for example, organ transplantation, lung disease and Type 1 diabetes.

OPPORTUNITY HIGHLIGHTS

• We are a small and flexible stem cell company.
• We are ready to launch a product in the cosmetics market.
• Our patented technologies are based on the richest source of MSCs ever described.
• We have a robust pre-clinical scientific foundation for our therapeutic claims.
• Our cells have generated a track record of efficacy from third-party users.

WHERE THEY ARE HEADED

We are on the cusp of launching a cosmetics product in Canada. This topical, dermal, cream is the first of its type to contain a human umbilical cord derivative and has potent skin rejuvenating and pain-relieving properties. We will follow this with an injectable formula that will be particularly important in the relief of joint pain and for which we have already accumulated robust pre-clinical data.

The cells themselves have been proven in pre-clinical studies to radically reduce inflammation, and one therapeutic indication is in the treatment of acute respiratory distress syndrome (ARDS) that kills patients, including COVID-19 patients, on respirators in hospital intensive care units. TRT has also spent several years, in concert with the Canadian Department of Defense, to demonstrate that these cells can be used as an efficient delivery vehicle for monoclonal antibodies, which represent some of the most expensive drugs on the market today.

MANAGEMENT TEAM

John E Davies BDS, PhD, DSc. FBSE. Founding President and CEO
TRT's technology platforms were developed by Davies from his academic research at the University of Toronto. He is internationally recognized as a leader in both biomaterials and mesenchymal stromal cell research.

Armand Keating MD, FRCSC, FRCPC. Founding Director and CMO
Keating is Professor of Medicine and also Biomedical Engineering at the University of Toronto; and a senior staff hematologist oncologist at Princess Margaret Cancer Centre, Toronto.

M Morris Hosseini PhD. Founding Director
Hosseini is a Senior Partner at Roland Berger in the Pharma & Healthcare Competence Center in Berlin, Germany. Prior to joining Roland Berger, Hosseini worked as a researcher in regenerative medicine; his Ph.D. is in Biomedical Engineering from the University of Toronto in Canada.

ABOUT THE OCMX™

The OCMX™ , established in 2009, is a next generation investor relations and marketing outreach firm. Through our online Ocmx portal, we connect companies with financial networks, generating interest and awareness for their opportunity.

Contact Us
The OCMX™
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: prosper@theocmx.com

Tissue Regeneration Therapeutics gets listed on THE OCMX™
https://theocmx.com/marketplace/tissue-regeneration-therapeutics/



---
Press release service and press release distribution provided by http://www.24-7pressrelease.com